Home News news015


AllTranz Developing Multi-Use Transdermal Patch


AllTranz, Lexington, Ky., is focused on the development of transdermal treatments for pain and other neurological disorders. The lead product in the company pipeline is a synthetic non-psychoactive cannabinoid delivered via gel. The initial indication is for the treatment of osteoarthritis. AllTranz also plans to develop a second generation of this product for the treatment of alcoholism. The gel product for arthritis pain is scheduled for a Phase 1 clinical trial by 2011. Another cannabinoid patch has been funded by the National Institutes of Health through a 2011 Phase 1 clinical trial. An abuse-deterrent opioid patch prototype has also been developed and is scheduled for preclinical toxicology testing in 2010. The AllTranz technology addresses not only pharmacological limitations, but the abuse potential which confounds the utility of current opioids.

AllTranz is focused on the design, synthesis, characterization, and testing of novel prodrugs—drugs with known clinical efficacy needing a chemical modification in order to go through the skin at a sufficient therapeutic rate. Prodrugs are a great method for permeation enhancement as they can improve drug solubility, stability, and potentially decrease skin irritation. AllTranz technical capabilities include drug synthesis (controlled substance schedule I-V), analytical method development (HPLC and LC-MS/MS), biological sample analysis, drug formulation, in vitro human skin diffusion studies, and pharmacokinetic studies in rats, hairless guinea pigs, and miniature swine.

Company intellectual property also includes an adjuvant technology for use with microneedle and other microporation systems, in order to extend single patch treatment duration to one week. Dr. Audra Stinchcomb, founder and chief scientific officer of AllTranz, is actively engaged in leveraging chemical techniques to develop new prodrug formulations and drug delivery platforms using unique transdermal drug delivery vehicles.

AllTranz is also actively pursuing corporate partnerships with companies interested in co-development of transdermal products of mutual interest.

Drug Discovery & Development

News & Events

  • Statins May Slow Progression Of Multiple Sclerosis, New Study Finds A UCSF-led study exa... Read more>>
  • FDA Requests More Information on Certriad LONDON (AP) - AstraZeneca PLC and Abbott Laborator... Read more>>
  • FDA Approves Mylan’s Drug Applications Mylan Inc. Monday announced that its subsidiary Mylan Ph... Read more>>
  • Novozymes Partnering With ProMetic Life Sciences Inc.Drug Discovery & Development - April 0... Read more>>
  • Food and Drug Administration NOTICES Meetings:   Internationa... Read more>>
  • U.S. Food & Drug Administration (FDA) New and Generic Drug Approvals Calan (verapamil h... Read more>>
  • AllTranz Developing Multi-Use Transdermal Patch   AllTranz, Lexington, Ky., is focused on t... Read more>>
  • Pending Litigation to Delay Launch of Generic Asacol Boehringer Ingelheim’s Roxane Laboratori... Read more>>
  • Proximagen Signs Deal With Upsher-Smith Proximagen Neuroscience plc, a biotechnology company... Read more>>
  • FDA Says Additional Pixuvri Trial Needed, CTI Opens Drug to Expanded Access Cell Therapeutics... Read more>>
  • T Cell Proliferation Assays ProImmune Ltd, a leader in epitope discovery, immunogenicity, an... Read more>>
  • in vivo Pharmacodynamic Assay Trevigen offers a validated assay with higher sensitivity and... Read more>>